Please turn JavaScript on

Drug Discovery and Development

Receive updates from Drug Discovery and Development for free, starting right now.

We can deliver them by email, via your phone or you can read them from a personalised news page on follow.it.

This way you won't miss any new article from Drug Discovery and Development. Unsubscribe at any time.

Site title: Drug Discovery & Development | Pharma and Biotech Insights

Is this your feed? Claim it!

Publisher:  Unclaimed!
Message frequency:  0.56 / day

Message History

The Bay Area-based pharma company Verseon began designing small-molecule drugs on a computational platform in 2002. That is well before most of the companies like Recursion and Exscientia now called AI drug discovery firms existed, and two decades before the launch of ChatGPT. Today, Verseon’s website states that its programs feature novel candidates that cannot…

The p...


Read full story

An investigational once-weekly tablet from Gilead and Merck maintained virologic suppression at Week 48 in two Phase 3 trials that enrolled a combined 1,209 adults with virologically suppressed HIV. The combination pairs 2 mg of Merck’s islatravir with 300 mg of Gilead’s lenacapavir. Participants assigned to the investigational arms cut treatment from seven pills a…

Th...


Read full story

Bristol Myers Squibb said Monday it will deploy an NVIDIA DGX SuperPOD, a prepackaged supercomputing platform that NVIDIA sells as a single standard unit, combining multiple compute racks, high-speed networking and management software into one cluster. BMS describes it as the “most powerful and energy-efficient single-owned NVIDIA infrastructure in life sciences.” That claim ...


Read full story

Eli Lilly has agreed to acquire AtaiBeckley for $2.8 billion upfront, plus up to $1 billion in contingent value rights, in a deal that could reach $3.8 billion. The acquisition would make Lilly the first large pharmaceutical company to build a full development program around a classic, explicitly Schedule I psychedelic, following AbbVie’s 2025 deal…

The post


Read full story

WTWH Media, the parent company of Drug Discovery & Development, announced on July 13 that it has renamed itself Arrowfly. The change applies to the corporate entity. DDD keeps its name, its URL, its newsletter, its editorial staff and its archives. The Cleveland-based company operates more than 40 B2B media brands and more than 45…

The post


Read full story